Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7467065 | 0.77 | GRIN1 (0.40) | IDO1TDO2AKR1A1AKR1B1KMT2A | |
| SCHEMBL5345525 | 0.75 | AKR1C3 (0.47) | IDO1AKR1A1AKR1B1KMT2AAKR1C3 | |
| SCHEMBL7467458 | 0.73 | CYP1A2 (0.44) | AKR1A1AKR1B1KMT2AAKR1C3PDK2 | |
| SCHEMBL4590370 | 0.72 | AKR1B1 (0.36) | AKR1B1KMT2AAKR1C3GRIN1GRIN2A | |
| SCHEMBL4590046 | 0.70 | MGAM (0.44) | IDO1AKR1A1AKR1B1KMT2AAKR1C3 | |
| SCHEMBL5678933 | 0.68 | KMT2A (0.39) | AKR1B1KMT2AGRIN1GRIN2APDK2 | |
| SCHEMBL7468833 | 0.68 | AKR1B1 (0.42) | AKR1B1KMT2AGRIN1GRIN2APDK2 | |
| SCHEMBL4589675 | 0.65 | PDE7A (0.37) | KMT2AAKR1C3GRIN1GRIN2APDK2 | |
| SCHEMBL7476921 | 0.63 | PDK2 (0.37) | AKR1B1GRIN1GRIN2APDK2 | |
| SCHEMBL7475963 | 0.62 | CACNB4 (0.39) | CACNG8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425566-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2008-09-16 | — | — | US | disclosed |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| US-6864277-B2 | 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-08 | — | — | US | disclosed |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | SANOFI-AVENTIS (FR) | 2003-08-28 | — | — | US | disclosed |
| EP-1296976-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sanofi-Aventis (FR) | 2003-04-02 | — | — | EP | disclosed |
| EP-0687251-B1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI SYNTHELABO (FR) | 2002-02-27 | — | — | EP | disclosed |
| WO-2001098295-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2001-12-27 | — | — | WO | disclosed |
| US-5773612-A | VASOPRESSIN OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5594023-A | 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-01-14 | — | — | US | disclosed |
| EP-0687251-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995018105-A1 | 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS | SANOFI (FR) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | AVPR1B, AVPR1A, AVPR2 | IDO1 2570/4885TDO2 4357/4885AKR1A1 353/4885 |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR1B, AVPR2, AVPR1A | IDO1 111/4885TDO2 748/4885AKR1A1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.